NOV 24, 2021 4:33 AM PST

Can Cannabis Treat Chemotherapy-induced Peripheral Neuropathy?

Platinum-based chemotherapies such as oxaliplatin are used to treat gastrointestinal tumors, especially in the advanced setting. Although demonstrated to be an effective treatment, it is one of the most neurotoxic types of chemotherapy. It has been shown that more than 90% of oxaliplatin recipients experience acute neuropathy. This neuropathy, known as chemotherapy-induced peripheral neuropathy (CIPN), can be highly debilitating. Currently, interventions to treat or prevent this condition are limited. The role of cannabis in treating cancer-related pain and certain neuropathic conditions has been studied. However, clinical evidence on the effectiveness of cannabis for treating CIPN is lacking. In February 2021, the results of a retrospective analysis evaluating cannabis for this treatment purpose were published.

In this review, the medical records of 768 patients who had received chemotherapy regimens, including oxaliplatin, were reviewed. Patients were separated into those with no cannabis use, those who used cannabis before oxaliplatin, and those who used cannabis after oxaliplatin. Results demonstrated a protective effect of cannabis that was statistically significant and more robust in those patients who used cannabis before treatment with oxaliplatin. Although this study was retrospective in nature, strengths of this study include data reliability and length of the study period.

The mechanism through which cannabis impacts CIPN is not well understood; however, the results of an animal study published in November 2021 suggest that oxaliplatin-induced neuropathy is modified by cannabis through specific cannabinoid receptors such as CB1. As such, potential therapeutic targets involving the endocannabinoid system are being described. Prospective trials further investigating the use of cannabis in the prevention and treatment of CIPN in humans are on the horizon.

 

Sources: Journal of Clinical Medicine, Therapeutic Advances in Medical Oncology, Neurotoxicity Research

About the Author
  • Dr. Christopher DiMaio is a Science Writer at Labroots. He received his MD from Penn State College of Medicine in 2014. His academic and professional interests include Neuroscience, Behavioral health, Immunology, and Healthcare improvement, among others. He is an active part of his community.
You May Also Like
JUN 11, 2021
Cannabis Sciences
Does Cannabis Interact with the COVID Vaccine?
JUN 11, 2021
Does Cannabis Interact with the COVID Vaccine?
As of June 10th 2021, 43% of people in the US aged 12 and over have been fully vaccinated for COVID-19, with 5 ...
JUN 28, 2021
Health & Medicine
Researchers Begin Clinical Trial to Test CBD in Autism
JUN 28, 2021
Researchers Begin Clinical Trial to Test CBD in Autism
Researchers at the University of California at San Diego plan to study whether CBD oil can be of help for children with ...
JUL 22, 2021
Health & Medicine
High Stress and Self Medication: Variables of Teenage Cannabis Use and Mental Health
JUL 22, 2021
High Stress and Self Medication: Variables of Teenage Cannabis Use and Mental Health
It is theorized that young members of the LGB community are thought to be heavier cannabis users. This heavier, and pote ...
AUG 12, 2021
Cannabis Sciences
Cannabis Cultivation Negatively Impacts the Environment
AUG 12, 2021
Cannabis Cultivation Negatively Impacts the Environment
Cannabis cultivation may have several damaging effects on the environment. The corresponding study was published in the& ...
AUG 18, 2021
Health & Medicine
Three-Fold Increase in Cannabis Use by People With Arthritis Pain
AUG 18, 2021
Three-Fold Increase in Cannabis Use by People With Arthritis Pain
Easing arthritis pain is thought to be a common reason for people to use cannabis, but there have been few statistics to ...
OCT 25, 2021
Health & Medicine
Latest Cannabis Extraction Developments
OCT 25, 2021
Latest Cannabis Extraction Developments
In response to the growing demand for concentrates, cannabis product manufacturers are exploring new technological advan ...
Loading Comments...